Insider Selling: Codexis (NASDAQ:CDXS) CEO Sells $12,142.14 in Stock

Codexis, Inc. (NASDAQ:CDXS – Get Free Report) CEO Alison Moore sold 10,651 shares of the firm’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $1.14, for a total transaction of $12,142.14. Following the sale, the chief executive officer owned 233,520 shares in the company, valued at approximately $266,212.80. The trade was a 4.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Alison Moore also recently made the following trade(s):

  • On Monday, October 12th, Alison Moore sold 6,335 shares of Codexis stock. The shares were sold at an average price of $1.36, for a total transaction of $8,615.60.

Codexis Trading Down 5.7%

CDXS opened at $0.99 on Friday. The stock has a market capitalization of $108.50 million, a P/E ratio of -4.95 and a beta of 2.38. The company has a current ratio of 2.81, a quick ratio of 2.99 and a debt-to-equity ratio of 0.58. Codexis, Inc. has a 12 month low of $0.90 and a 12 month high of $2.98. The firm’s fifty day simple moving average is $1.25 and its 200 day simple moving average is $1.77.

Codexis (NASDAQ:CDXS – Get Free Report) last released its earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. Codexis had a negative return on equity of 43.24% and a negative net margin of 21.77%. The firm had revenue of $19.26 million during the quarter, compared to analysts’ expectations of $18.72 million. As a group, research analysts anticipate that Codexis, Inc. will post -0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on CDXS. Benchmark reaffirmed a “hold” rating on shares of Codexis in a research report on Thursday, August 20th. Weiss Ratings raised Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 23rd. Stephens restated an “overweight” rating and issued a $5.00 target price on shares of Codexis in a research note on Monday, November 16th. Wall Street Zen raised Codexis from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Finally, Piper Sandler reduced their price target on Codexis from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, August 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.00.

Get Our Latest Stock Analysis on Codexis

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Aberdeen Group plc lifted its position in Codexis by 59.5% during the 3rd quarter. Aberdeen Group plc now owns 10,797,702 shares of the biotechnology company’s stock worth $15,009,000 after buying an additional 4,027,748 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Codexis during the 2nd quarter worth about $16,463,000. Nantahala Capital Management LLC acquired a new position in shares of Codexis during the 2nd quarter worth about $8,189,365. Assenagon Asset Management S.A. grew its holdings in shares of Codexis by 70.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,278,206 shares of the biotechnology company’s stock valued at $2,889,000 after acquiring an additional 527,036 shares in the last quarter. Finally, Private Advisor Group LLC bought a new position in shares of Codexis in the 3rd quarter valued at about $1,677,000. Institutional investors own 78.54% of the company’s stock.

Codexis Company Profile

(Get Free Report)

Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.

Read More

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.